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We thank Roosenboom et al. for their interest in our paper exploring 
the relative expression of αE integrin in the colon and ileum in inflam-
matory bowel disease [IBD] patients and in healthy subjects. The αE 
integrin [CD103] is a cell surface molecule that forms a heterodimer 
with β7 integrin and, through interactions with E-cadherin, serves to 
retain αEβ7-expressing cells at mucosal surfaces.1 Therapeutic treat-
ment with etrolizumab, which binds to β7 integrin and blocks both 
α4β7:MAdCAM-1 as well as αEβ7:E-cadherin interactions, led to 
a reduction in crypt-associated αE+ cell numbers in a phase 2 clini-
cal trial.2 Baseline levels of colonic αE expression were also associ-
ated with remission in a post-hoc analysis of the same study.2 Our 
present study was designed to evaluate the prevalence and localiza-
tion of αE+ cells in the colon and ileum and the potential impact of 
inflammation and concomitant medication on αE expression.3 We 
found αE expression to be stable and not dependent on either con-
comitant medications or degree of inflammation. These findings are 
of importance given the future potential of biopsy-based predictive 
biomarker assessment for etrolizumab treatment.
Roosenboom et al. suggest that the role of αE+ cells in IBD patho-
biology is not currently understood.4 While studies are on-going, 
previous work from our labs and others using enzymatic diges-
tion of intestinal biopsies has shown that αE integrin is expressed 
on approximately 90% of intraepithelial lymphocytes in the intes-
tine, 40% of T cells in the lamina propria, and <3% of circulating 
T lymphocytes.5,6 As many αE+ cells are intra-epithelial, appropri-
ate digestion of tissue prior to analysis is critical and studies that 
have used only mechanical isolation of cells have shown lower levels 
of αE+ cells with high variability.7 Mechanical isolation techniques 
have been demonstrated to result in low cell yield, functional altera-
tions8 and inversion of the CD4:CD8 ratio9 that may affect the inter-
pretation of studies that have not used enzymatic digestion.7,10 Our 
previous studies using enzymatic digestion have shown a potential 
inflammatory role for CD4+αE+ T helper cells,6,11 more interferon-γ 
in αE+ CD8+ T cells,6 and a striking increase in tissue αE+ CD4 T 
cells during inflammation in ulcerative colitis.12 Other groups have 
shown that αE is induced on Th9 cells, a key CD4 helper T cell 
population in vitro, and blockade of both αEβ7 and α4β7 is superior 
to blockade of α4β7 in inhibiting homing of these cells, as well as 
CD8 T cells, to the inflamed intestine.13 Taken together, these data 
implicate αE+ T cells in the pathophysiology of IBD.
Personalized medicine has been identified as a major unmet 
research need of importance to patients and clinicians in IBD,14 and 
has the potential to direct the right treatment to the right patient at 
the right time, thereby maximizing the likelihood of a positive clini-
cal outcome whilst aiming to minimize risk of side effects and cost. 
The potential utility of αE or other genes11 as predictive biomarkers 
for etrolizumab is being tested prospectively in on-going phase 3 
clinical trials. To reach the goal of personalized medicine for IBD 
patients, predictive biomarkers such as αE for etrolizumab must be 
prospectively tested as well as evaluated in patient datasets to move 
the field forward.
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